The Food and Drug Administration and Pfizer changed the package insert for irinotecan to
include a patient's UGT1A1*28 genotype as a risk factor for severe neutropenia on the basis …

Mutations in the genes encoding isocitrate dehydrogenase, IDH1 and IDH2, have been
reported in gliomas, myeloid leukemias, chondrosarcomas and thyroid cancer. We discovered …

Tamoxifen is the most widely used anti-oestrogen for the treatment of hormone-dependent
breast cancer. The pharmacological activity of tamoxifen is dependent on its conversion by …

Irinotecan is a camptothecin analog used as an anticancer drug. Severe, potentially life-threatening
toxicities can occur from irinotecan treatment. Although multiple genes may play a …

Variation in drug efficacy and toxicity remains an important clinical concern. Presently, single
nucleotide polymorphisms (SNPs) only explain a portion of this problem, even in situations …

Purpose: To evaluate the effect of thymidylate synthase (TYMS) and methylenetetrahydrofolate
reductase (MTHFR) genotypes on toxicity in patients treated with capecitabine for …

Rationale: IgE antibodies to the mammalian oligosaccharide galactose-α-1,3-galactose (α-gal)
are common in the southeastern United States. These antibodies, which are induced by …

Atazanavir (ATV) plasma concentrations are influenced by CYP3A4 and ABCB1, which are
regulated by the pregnane X receptor (PXR; NR1I2). PXR expression is correlated with …

Purpose: Irinotecan is an important drug for the treatment of solid tumors. Although genes
involved in irinotecan pharmacokinetics have been shown to influence toxicity, there are no …

Background: There is a large degree of variation in tumour response and host toxicities
associated with neoadjuvant chemoradiation for rectal cancer patients. We performed a …